117 related articles for article (PubMed ID: 30198974)
21. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.
Yoo J; Choi JY; Moon SH; Bae DS; Park SB; Choe YS; Lee KH; Kim BT
Int J Gynecol Cancer; 2012 Sep; 22(7):1226-33. PubMed ID: 22810970
[TBL] [Abstract][Full Text] [Related]
22. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma.
Li C; Zhang J; Chen S; Huang S; Wu S; Zhang L; Zhang F; Wang H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):306-315. PubMed ID: 29110068
[TBL] [Abstract][Full Text] [Related]
24. Basal (18)F-FDG PET/CT in follicular lymphoma: A comparison of metabolic and clinical variables in the prognostic assessment.
Jiménez Londoño GA; García Vicente AM; Poblete García VM; Amo-Salas M; Calle Primo C; Ibañez García Á; Martínez Sanchís B; López-Fidalgo JF; Solano Ramos F; Martínez Hellín A; Díaz Morfa M; Soriano Castrejón Á
Rev Esp Med Nucl Imagen Mol; 2016; 35(5):298-305. PubMed ID: 27312693
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
26. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
28. The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma.
Lawal IO; Nyakale NE; Harry LM; Modiselle MR; Ankrah AO; Msomi AP; Mokgoro NP; Boshomane TG; de Wiele CV; Sathekge MM
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2025-2033. PubMed ID: 28660348
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
30. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
31. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Total Lesion Glycolysis Measured by 18F-FDG-PET/CT in Patients with Colorectal Cancer.
Ogawa S; Itabashi M; Kondo C; Momose M; Sakai S; Kameoka S
Anticancer Res; 2015 Jun; 35(6):3495-500. PubMed ID: 26026116
[TBL] [Abstract][Full Text] [Related]
36. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
37. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma.
Kasenda B; Haug V; Schorb E; Fritsch K; Finke J; Mix M; Hader C; Weber WA; Illerhaus G; Meyer PT
J Nucl Med; 2013 Feb; 54(2):184-91. PubMed ID: 23249539
[TBL] [Abstract][Full Text] [Related]
39. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]